Forge Biologics | Manufacturing Gene Therapies for Life
o
About

Mission

Our foundation is hope

Enable access to life-changing gene therapies and help bring them from idea into reality.

Our mission is to enable access to life-changing gene therapies and help bring them from idea into reality. We partner with innovators in the gene therapy community and bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them the most.

About

Approach

Our foundation is hope

Forge is a CDMO built for gene therapy developers, by gene therapy developers. We provide the scale, manufacturing expertise, and technology to accelerate gene therapies for genetic diseases.

Forge is redefining the concept of a genetic medicine CDMO. For our team of industry veterans, developing successful genetic medicines is about enabling access for patients faster, safer, and at scale. We are gene therapy developers, researchers, and clinicians, that built Forge to solve for the pain points we experienced when developing gene therapy programs. Our goal is to provide our collective expertise, services, and technology so that your therapies can get to patients who need them the most and create lasting impact. We see ourselves as partners in this endeavor and look forward to playing a role in bringing your mission to life.

As a hybrid contract manufacturing and clinical-stage therapeutics development company, we are a true gene therapy development engine bringing together access to quality, in-house manufacturing, the experience of our team in gene therapy product development, and an exciting pipeline of new therapies for patients.

About

Our Story

Our foundation is hope

Forge Biologics was founded in 2020 by Timothy J. Miller, Ph.D., Jaysson Eicholtz, and Erandi De Silva, Ph.D., who shared a vision to give people suffering from genetic diseases hope.

Since our founding, we’ve built a 200,000 sq. ft. custom designed cGMP facility, the Hearth, developed our proprietary platform technology, and built a team of diverse, driven, and passionate people working together to trailblaze a new model for how we make medicines to treat patients with genetic diseases.

In 2023, Forge joined Ajinomoto Group, a global business investing in our long-term growth for the benefit of our clients and their patients.

About

Leadership

Our foundation is hope

Executive Officers

Timothy J. Miller, Ph.D.

President & Chief Executive Officer

Our foundation is hope
Timothy J. Miller, Ph.D.

President & Chief Executive Officer

Our foundation is hope
Yasuyuki Otake

Chair

Our foundation is hope
David Dismuke, Ph.D.

Chief Technical Officer

Our foundation is hope
John Maslowski

Chief Commercial Officer

Our foundation is hope
Tatsuya Okuzumi

Chief Global Coordination
Officer, Forge Biologics
General Manager, Planning Group,
Bio-Pharma Services Department,
Ajinomoto Co.

Our foundation is hope
Christina Perry

Chief Financial Officer

Our foundation is hope
Christopher Shilling

Chief Regulatory Officer

Our foundation is hope

Department Officers

Maria Escolar, M.D.

Chief Medical Officer

Our foundation is hope
Magdalena Tyrpien

Chief Business Officer

Our foundation is hope
About

Scientific & Manufacturing Advisory Board 

Our foundation is hope
Steven J. Gray, Ph.D.

UT Southwestern

Robert Kotin, Ph.D.

Stealth Newco

Karen Kozarsky, Ph.D.

SwanBio Therapeutics

Haiyan Ma, Ph.D.

Northern Biomolecular Services

Simon Waddington, Ph.D.

University College London

5/5 (1 Review)